InvestorsHub Logo

lolroflmao

07/03/20 11:51 AM

#862 RE: Fress #861


A steak may feed the hunger yet, the difference is in 'how' it was made that gains the ultimate satisfaction.


BTW, that other link is 9/10yr old!!!

QuitinMyJob

07/03/20 11:53 AM

#863 RE: Fress #861

Dress, it looks like the drug failed because of the adverse side effects in 80% of patients. Brother we didn't get to skip Phase 2 for no reason at all. Anyone selling because of another companies bad news could miss out. There isn't many companies in the Phase 3 trials. I think we are still okay here.


https://www.clinicaltrialsarena.com/news/kevzara-us-covid19-trial-data/

ReikoBlack

07/03/20 11:57 AM

#865 RE: Fress #861

What? After all your pumping, telling everyone to hold for dollars, you now have doubts about RVVTF?

You never answered my question.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156601574

Regeneron's Arthritis Drug Fails COVID-19 Trial

https://www.fool.com/investing/2020/07/03/regenerons-rheumatoid-arthritis-drug-fails-covid-1.aspx

This is why RVV is tanking if Regeneron Arthritis drug failed I'm losing hope on this ticker. Hopefully the IND doesn't get delayed or this will really tank hard. I knew I should sold between .40-.50 always lock in profits and don't fall in love with a stock or it's story.


A Multicentre Trial of Bucillamine in the Treatment of Early Rheumatoid Arthritis (SNOW Study)

https://pubmed.ncbi.nlm.nih.gov/21188453/

This sucks!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!


$RVVTF

powerbattles

07/03/20 1:24 PM

#889 RE: Fress #861

Regeneron Pharmaceuticals Inc and Sanofi their drug Kevzara failed to meet the main goals of a U.S. Doesn't mean Bucillamine fail too. Chit look at the side effects KEVZARA it's easy to tell why KEVZARA won't work. On other hand Bucillamine the drug works by helping restore and enhance an antioxidant called glutathione. Revive has a history of repurposing drugs and IP such as Bucillamine, a cysteine that has been used for more than 30 years with an impeccable track record for safety.

“We are very pleased in achieving this major milestone of filing our IND for a Phase 3 confirmatory study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19, which was based on the recommendation from the U.S. FDA from our pre-IND meeting earlier this year,” said Michael Frank, Revive’s Chief Executive Officer. “We are preparing plans for initiating the Phase 3 study upon the IND becoming active by the U.S. FDA and we look forward to advancing Bucillamine as a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally.”
https://www.globenewswire.com/news-release/2020/06/30/2055779/0/en/Revive-Therapeutics-Announces-Submission-of-Investigational-New-Drug-Application-IND-with-U-S-FDA-for-Phase-3-Confirmatory-Study-for-Bucillamine-in-COVID-19.html

KEVZARA® (sarilumab) can cause serious side effects including:
SERIOUS INFECTIONS: KEVZARA is a medicine that affects your immune system. KEVZARA can lower the ability of your immune system to fight infections. Some people have had serious infections while using KEVZARA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting KEVZARA. Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with KEVZARA.


https://www.kevzara.com/?&utm_source=google&utm_medium=cpc&utm_campaign=Google_Kevzara+DTC_Brand_Core_BMM&utm_term=%2Bsarilumab&gclid=EAIaIQobChMI4IWZ7MWx6gIVxcDACh0cGQsMEAAYASAAEgKeYvD_BwE&gclsrc=aw.ds


Bucillamine: A Potent Thiol Donor with Multiple Clinical Applications:

Bucillamine is an antirheumatic agent developed from tiopronin. It is mainly used in Japan and Korea. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation
https://en.wikipedia.org/wiki/Bucillamine

Case study:
"until recently there has been no report on an association between BOOP and bucillamine. We describe a patient with RA who developed BOOP during the treatment of bucillamine.
http://www.kjim.org/journal/view.php?number=8022

Is Bucillamine a potential treatment for lung inflammation?
https://business.financialpost.com/business-trends/is-bucillamine-a-potential-treatment-for-lung-inflammation